Open an account

Pasithea Therapeutics

KTTA · NASDAQ

$0.41−$0.0023 (−0.56%)TodayMarket closed ·
Prev close $0.4123

KTTA analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 3 analysts

Average $3.06 (+646.3% upside)

Low
$3.03
Now
$0.41
High
$3.15

Upgrades and downgrades

The latest rating actions, newest first

KTTA analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Jun 16, 2026MaintainsBuy
HC Wainwright & Co.Apr 20, 2026MaintainsBuy
HC Wainwright & Co.Dec 8, 2025InitiatesBuy

The case for and against

Updated Oct 8, 2026

Bull case

Pasithea Therapeutics is attractive fundamentally because PAS-004 targets the RAS/MAPK pathway with a differentiated macrocyclic MEK-inhibitor design, aiming to overcome the resistance, toxicity, and limited durability that constrain older MEK drugs. The program has meaningful regulatory validation through Orphan Drug, Fast Track, and Rare Pediatric Disease Designation, which also creates potential Priority Review Voucher value that has been cited at $150 million to $250 million, while early Phase 1/1b data and the advanced cancer study suggest safety, tolerability, and pharmacologic breadth. The recent extension of treatment duration to up to 18 months and added MRI/CN measurements should deepen the efficacy dataset, improve durability assessment, and strengthen optionality across NF1-PN, NF1-CN, and broader oncology markets.

Bear case

Pasithea Therapeutics is a speculative biotechnology company whose value depends almost entirely on the success of its early-stage pipeline, including PAS-004, PAS-003, and PAS-001, across highly uncertain CNS disorders, RASopathies, and cancers. The cited risks of failed or inconclusive clinical trials, inadequate funding to advance drugs through development, and dilutive capital raises underscore a fragile financing profile and a business model that has yet to demonstrate durable clinical or commercial validation. With a single reportable segment centered on research and development rather than recurring product revenue, the company remains exposed to binary trial outcomes and shareholder dilution, which supports a negative outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.